Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer

NCT00051584 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00051584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00051584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
Not reported
Completion date
May 31, 2003
Enrollment
60
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms